Alphamab Oncology (FRA:3NK)

Market Cap	967.80M +153.1%
Revenue (ttm)	93.42M +207.2%
Net Income	27.67M
EPS	0.03
Shares Out	n/a
PE Ratio	34.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	22
Open	0.9750
Previous Close	0.9450
Day's Range	0.9750 - 0.9750
52-Week Range	0.4980 - 1.6800
Beta	n/a
RSI	47.42
Earnings Date	Mar 27, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 484
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3NK

Financial Performance

Financial numbers in CNY